Biotech Investors are Hungry for the Next Big Buyout Target
GT Biopharma, Inc. (GTBP) has been buiding momentum over the last few days which have followed (GTBP)’s last announcement that they will Present Data on Next Generation TriKE (OXS-C3550)! But what’s more is that the company specifically said that OXS-3550 is expected to enter human clinical trials in 2018! The new year is right around the corner, which means that this could be a critical time to be paying close attention to (GTBP)!
Astellas Purchases DMD Drug For $450 Million
Japan-based biotech Asetllas has bought its partner Mitobridge in a deal worth up to $450 million. The acquisition gives Astellas full reign of a phase1 Duchenne muscular dystrophy (DMD) drug in exchange $225 million upfront and the same amount at a later time.
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,050,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to January 1, 2018 to publicly disseminate information about (GTBP). We own zero shares.